



## OPEN ACCESS

APPROVED BY  
Frontiers Editorial Office,  
Frontiers Media SA, Switzerland

\*CORRESPONDENCE  
Per thor Straten  
per.thor.straten@regionh.dk

SPECIALTY SECTION  
This article was submitted to  
Cancer Immunity  
and Immunotherapy,  
a section of the journal  
Frontiers in Immunology

RECEIVED 15 June 2022  
ACCEPTED 11 July 2022  
PUBLISHED 05 August 2022

CITATION  
Simões AMC, Holmström MO,  
Aehnlich P, Rahbech A, Peeters MJW,  
Radziwon-Balicka A, Zamora C,  
Klausen TW, Skov V, Kjær L, Ellervik C,  
Fassi DE, Vidal S, Hasselbalch HC,  
Andersen MH and Straten Pt (2022)  
Corrigendum: patients with  
myeloproliferative neoplasms harbor  
high frequencies of CD8 T cell-  
platelet aggregates associated with  
T cell suppression.  
*Front. Immunol.* 13:970322.  
doi: 10.3389/fimmu.2022.970322

COPYRIGHT  
© 2022 Simões, Holmström, Aehnlich,  
Rahbech, Peeters, Radziwon-Balicka,  
Zamora, Klausen, Skov, Kjær, Ellervik,  
Fassi, Vidal, Hasselbalch, Andersen and  
Straten. This is an open-access article  
distributed under the terms of the  
[Creative Commons Attribution License  
\(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or  
reproduction in other forums is  
permitted, provided the original  
author(s) and the copyright owner(s)  
are credited and that the original  
publication in this journal is cited, in  
accordance with accepted academic  
practice. No use, distribution or  
reproduction is permitted which does  
not comply with these terms.

# Corrigendum: Patients with myeloproliferative neoplasms harbor high frequencies of CD8 T cell-platelet aggregates associated with T cell suppression

Ana Micaela Carnaz Simões<sup>1</sup>, Morten Orebo Holmström<sup>1</sup>, Pia Aehnlich<sup>1</sup>, Anne Rahbech<sup>1</sup>, Marlies J. W. Peeters<sup>1</sup>, Aneta Radziwon-Balicka<sup>1</sup>, Carlos Zamora<sup>2</sup>, Tobias Wirenfeldt Klausen<sup>1</sup>, Vibe Skov<sup>3</sup>, Lasse Kjær<sup>3</sup>, Christina Ellervik<sup>4,5,6</sup>, Daniel El Fassi<sup>4,7</sup>, Silvia Vidal<sup>2</sup>, Hans Carl Hasselbalch<sup>3</sup>, Mads Hald Andersen<sup>1,8</sup> and Per thor Straten<sup>1,8\*</sup>

<sup>1</sup>Department of Oncology, National Center for Cancer Immune Therapy (CCIT-DK), Herlev University Hospital, Herlev, Denmark, <sup>2</sup>IIB-Sant Pau- Institut Rec. Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, <sup>3</sup>Department of Hematology, Zealand University Hospital, Roskilde, Denmark, <sup>4</sup>Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark, <sup>5</sup>Department of Laboratory Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA, United States, <sup>6</sup>Department of Data and Innovation Support, Region Zealand, Sorø, Denmark, <sup>7</sup>Department of Hematology, Rigshospitalet University Hospital, Copenhagen, Denmark, <sup>8</sup>Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

## KEYWORDS

platelets, platelet-bound T cells, platelet-T cell aggregates, Myeloproliferative Neoplasms (MPN), CALR mutation, JAK2 mutation

## A Corrigendum on:

**Patients With Myeloproliferative Neoplasms Harbor High Frequencies of CD8 T Cell-Platelet Aggregates Associated With T Cell Suppression.**

Carnaz Simões AM, Holmström MO, Aehnlich P, Rahbech A, Peeters MJ, Radziwon-Balicka A, Zamora C, Wirenfeldt Klausen T, Skov V, Kjær L, Ellervik C, Fassi DE, Vidal S, Hasselbalch HC, Andersen MH and thor Straten P (2022)*Front. Immunol.* 13:866610.  
doi: 10.3389/fimmu.2022.866610

In the published article, there was an error in the author list, and author Marlies J. W. Peeters was erroneously omitted. The corrected author list appears below.

**Ana Micaela Carnaz Simões<sup>1</sup>, Morten Orebo Holmström<sup>1</sup>, Pia Aehnlich<sup>1</sup>, Anne Rahbech<sup>1</sup>, Marlies J. W. Peeters<sup>1</sup>, Aneta Radziwon-Balicka<sup>1</sup>, Carlos Zamora<sup>2</sup>, Tobias Wirenfeldt Klausen<sup>1</sup>, Vibe Skov<sup>3</sup>, Lasse Kjær<sup>3</sup>, Christina Ellervik<sup>4-6</sup>,**

**Daniel El Fassi<sup>4,7</sup>, Silvia Vidal<sup>2</sup>, Hans Carl Hasselbalch<sup>3</sup>, Mads Hald Andersen<sup>1,8</sup> and Per thor Straten<sup>\*1,8</sup>**

<sup>1</sup>Department of Oncology, National Center for Cancer Immune Therapy (CCIT-DK), Herlev University Hospital, Herlev, Denmark.

<sup>2</sup>IIB-Sant Pau- Institut Rec. Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

<sup>3</sup>Department of Hematology, Zealand University Hospital, Roskilde, Denmark.

<sup>4</sup>Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

<sup>5</sup>Department of Laboratory Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA, United States.

<sup>6</sup>Department of Data and Innovation Support, Region Zealand, Sorø, Denmark.

<sup>7</sup>Department of Hematology, Rigshospitalet University Hospital, Copenhagen, Denmark

<sup>8</sup>Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.